INDOCO REMEDIES LIMITED (INDOCO): Financials & Fundamentals History

Share price

Closing priceAdjusted for splits and bonus issues.

3M1Y3YAll

₹219.34 latest close · −10.1% over the last 90 sessions

₹219.34 month-end · −14.4% over 12 months

₹219.34 month-end · −39.5% over 3 years

₹219.34 month-end · +18.9% since Jan '19

52-week range ₹162.19 to ₹288.00 · 1-year volatility 49.5%

Was the rally earned?

3 years5 years

-40%share price, 3 yearsEarnings-driven

Mostly earnings.

Per-share earnings took off 254 points, while the multiple moved less (P/E 23.5x to 359.6x).
The share count fell 3%.

Net profit growth-256 ptsNet profit fell about 96%, which lowers the price.

P/E change+215 ptsThe P/E rose from 23.5x to 359.6x, which lifts the price.

Share count change+2 ptsShare count fell 3%, which lifts the price.

-44%share price, 5 yearsEarnings-driven

Mostly earnings.

Per-share earnings took off 214 points, while the multiple moved less (P/E 38.4x to 359.6x).
The share count fell 3%.

Net profit growth-216 ptsNet profit fell about 94%, which lowers the price.

P/E change+170 ptsThe P/E rose from 38.4x to 359.6x, which lifts the price.

Share count change+2 ptsShare count fell 3%, which lifts the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 1 year: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-68.4%not yet recovered

1-year volatility49.5%annualised

Beta vs sector index0.913-year daily, correlation 0.31

Volume spikes11last 90 sessions, 5x the 50-day median

Drawdown from peak

Largest drawdowns

-68.4% (2021-08 peak to 2026-03 low, not yet recovered)

-41.8% (2020-02 peak to 2020-03 low, recovered 2020-09)

-39.3% (2019-01 peak to 2019-08 low, recovered 2020-01)

Most recent volume spikes

2026-10-27: 10.8x the 50-day median, price +0.5% that day

2026-10-15: 10.7x the 50-day median, price +2.9% that day

2026-09-30: 8.8x the 50-day median, price -2.8% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

359.6xP/E todayNear its historic high

Against its own history98th percentile

CheapestMedian 38.4xDearest

Usual range 20.6x to 113.2x since 2019-01.

Against Health Technology359.6x vs 37.0x

This company

359.6x

Sector median

37.0x

872% above the Health Technology median.

P/EP/BP/S

P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

ROCE11th▲ 3 pts vs a year ago
Op. margin25th▲ 8 pts vs a year ago
Revenue growth50th▲ 40 pts vs a year ago
EPS growth3rd▼ 6 pts vs a year ago
Debt/equity ↓5thflat vs a year ago
Cash cycle ↓48th▲ 23 pts vs a year ago
P/E ↓2nd
12M momentum22nd▼ 23 pts vs a year ago

Rank history

ROCE

Op. margin

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26

Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~25%annual earnings growth implied by the price

At a P/E of 46.7x, the price would imply about 24.8%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Fewer than six years of annual earnings are available, which is too little to measure delivered growth.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov: ₹219.34
P/E: 359.6x
ROCE: 1.0%
Market Cap: ₹2028 cr
Revenue (TTM): ₹1874 cr
P/S: 1.1x
P/B: 2.2x
ROE: 0.6%
Operating Margin: 9.0%
Debt / Equity: 1.2x
Promoter Holding: 58.9%
12M Momentum: -14.4%

52-week range

₹162.19₹288.00

45% of the way from its 52-week low to its high

Price risk

1Y volatility

49.5%

Beta vs sector

1-year daily

1.09

Balance sheet & cash

Interest cover

operating profit ÷ interest

1.1x

Cash from profit, 3Y

operating cash flow ÷ net profit

2.68x

Share count, 1Y

unchanged

Are profits backed by cash?

1 of 6checks within range2 beyond a threshold

Other income reliance300%Beyond threshold

Other income as a share of pre-tax profit (trailing twelve months): 300.0%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate-5%Beyond threshold

Median quarterly effective tax rate over about 2.5 years: -5.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion—Not enough data

Not enough reported data to compute this.

Free cash flow2 of 5 yrsNear threshold

Fiscal years with positive free cash flow in the last 5: 2. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+20 daysNear threshold

Debtor days are above the median of the previous three fiscal years by 20 days (97 vs 77). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress8% of fixed assetsWithin range

Capital work-in-progress is 8% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+108 days / 2 yrsNear threshold

Days payable changed by +108 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Over 3 years, institutional and promoter holdings were broadly unchanged.
The number of shareholders fell from 36,588 to 32,457 (-11%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change

Promoters58.8%58.9%+0.1 pts

FIIs1.6%1.3%-0.3 pts

DIIs17.8%17.7%-0.1 pts

Public and others21.9%22.0%+0.2 pts

Number of shareholders

32,457shareholders-11% since Sep '23

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−22.2%typical 12-month return vs the marketBelow the base rate

We found 50 past situations where a non-financial company looked like INDOCO REMEDIES LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −32% to +6% vs the market, against −8% for all non-financial companies in the same months.
The analogs' median sat below that base rate (gap −14.7%, 80% range −21.9% to −6.6%), but the matches cluster in only 6 distinct 12-month windows.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 2 beyond the range shown, drawn at the edge

Similar setups' median

−22.2%

All companies' median

−7.5%

Beat the market

28% vs 42%

50 past situations · 50 companies · 29 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
BASML Process Industries	Jan 2021	146x	6%	+6%	−13%	+36%
KOLTEPATIL Finance	May 2025	220x	2%	−8%	−15%	−12%
GLOBUSSPR Consumer Non-Durables	Sep 2025	119x	6%	−15%	−21%	−25%
SNOWMAN Commercial Services	Feb 2023	338x	3%	+1%	−22%	+51%
GREENLAM Non-Energy Minerals	Sep 2025	179x	7%	−6%	−21%	−12%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
VALIANTORG Process Industries	Sep 2025	184x	3%	−19%	−33%	+38%
NUVOCO Non-Energy Minerals	Feb 2023	389x	4%	+1%	−23%	−37%
CENTUM Electronic Technology	May 2024	230x	8%	+70%	−16%	+36%

How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: drawdown from 12-month high, 12-month momentum and operating margin. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to INDOCO REMEDIES LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

CAMLIN FINE SCIENCESCAMLINFINE

Process Industries

69%similar

revenueP/E

ESTER INDUSTRIESESTER

Process Industries

69%similar

debt/equityROCE

HINDWARE HOME INNOVATIONHINDWAREAP

Producer Manufacturing

68%similar

debt/equityoperating margin

KITEX GARMENTSKITEX

Process Industries

68%similar

debt/equityrevenue growth

NACL INDUSTRIESNACLIND

Process Industries

65%similar

P/EEPS growth

DISHMAN CARBOGEN AMCISDCAL

Health Technology

72%similar

operating marginpromoter holding

HIKALHIKAL

Health Technology

61%similar

operating marginrevenue

KOPRANKOPRAN

Health Technology

49%similar

operating marginvolatility

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Jul '23

2026
OctPriceVolume reached 10.8x its 50-day median on 2026-10-27; price +0.5% that day.
SepResultsEPS (TTM) turned positive.
SepValuationP/E crossed above the 90th percentile of its own history to date (429.0x).
SepPriceVolume reached 205.2x its 50-day median on 2026-09-02; price +12.3% that day.
AugPeer rankMoved into the 3rd quartile of Health Technology on operating margin (from the bottom quartile).
JunResultsRevenue (TTM) reached a new high of ₹1,846 cr.
JunDebtDebt / equity rose above 1.0x (1.16x).
JunPriceVolume reached 145.8x its 50-day median on 2026-06-11; price +18.6% that day.

Show 22 earlier events

2026
MarPriceFell 68% from the Aug 2021 peak to the Mar 2026 low.
MarPeer rankSlipped to the bottom quartile of Health Technology on operating margin (from the 3rd quartile).
FebPriceVolume reached 25.5x its 50-day median on 2026-02-03; price +10.7% that day.
2025
DecPeer rankMoved into the 3rd quartile of Health Technology on operating margin (from the bottom quartile).
OctPriceVolume reached 45.2x its 50-day median on 2025-10-13; price +3.3% that day.
SepPriceVolume reached 89.2x its 50-day median on 2025-09-11; price +11.5% that day.
JunPeer rankSlipped to the bottom quartile of Health Technology on ROCE (from the 3rd quartile).
JunDividendDividend payout cut from 14% to -2% of profit.
MayPriceVolume reached 7.9x its 50-day median on 2025-05-22; price -7.2% that day.
MarResultsEPS (TTM) turned negative.
MarPriceVolume reached 16.5x its 50-day median on 2025-03-03; price +14.2% that day.
2024
DecPeer rankSlipped to the bottom quartile of Health Technology on operating margin (from the 3rd quartile).
DecPriceVolume reached 26.0x its 50-day median on 2024-12-03; price -0.5% that day.
AugPriceVolume reached 10.6x its 50-day median on 2024-08-21; price +4.8% that day.
JunResultsRevenue (TTM) reached a new high of ₹1,817 cr.
JunPeer rankSlipped to the 3rd quartile of Health Technology on ROCE (from the 2nd quartile).
MayValuationP/E fell below the 10th percentile of its own history to date (19.5x).
AprPriceVolume reached 9.2x its 50-day median on 2024-04-05; price +1.7% that day.
JanPriceVolume reached 6.6x its 50-day median on 2024-01-18; price -0.4% that day.
2023
NovPriceVolume reached 8.5x its 50-day median on 2023-11-28; price +3.5% that day.
SepPriceVolume reached 16.9x its 50-day median on 2023-09-13; price +6.3% that day.
JulValuationP/E fell below the 10th percentile of its own history to date (20.5x).

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history95 months · 2019-01 to 2026-11

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-11	359.6x	₹1874 cr	0.6%	1.0%	1.2x
2026-10	341.5x	₹1874 cr	0.6%	1.0%	1.2x
2026-09	429.0x	₹1874 cr	0.6%	1.0%	1.2x
2026-08	—	₹1846 cr	-10.8%	1.0%	1.2x
2026-07	—	₹1846 cr	-10.8%	1.0%	1.2x
2026-06	—	₹1846 cr	-10.8%	1.0%	1.2x
2026-05	—	₹1760 cr	-11.6%	0.0%	1.0x
2026-04	—	₹1760 cr	-11.6%	0.0%	1.0x
2026-03	—	₹1760 cr	-11.6%	0.0%	1.0x
2026-02	—	₹1726 cr	-11.5%	0.0%	1.0x
2026-01	—	₹1726 cr	-11.5%	0.0%	1.0x
2025-12	—	₹1726 cr	-11.5%	0.0%	1.0x
2025-11	—	₹1674 cr	-11.6%	0.0%	1.0x
2025-10	—	₹1674 cr	-11.6%	0.0%	1.0x
2025-09	—	₹1674 cr	-11.6%	0.0%	1.0x
2025-08	—	₹1665 cr	-7.8%	0.0%	1.0x
2025-07	—	₹1665 cr	-7.8%	0.0%	1.0x
2025-06	—	₹1665 cr	-7.8%	0.0%	1.0x
2025-05	—	₹1725 cr	-1.3%	10.0%	0.6x
2025-04	—	₹1725 cr	-1.3%	10.0%	0.6x
2025-03	—	₹1725 cr	-1.3%	10.0%	0.6x
2025-02	56.6x	₹1773 cr	2.8%	10.0%	0.6x
2025-01	72.0x	₹1773 cr	2.8%	10.0%	0.6x
2024-12	95.7x	₹1773 cr	2.8%	10.0%	0.6x
2024-11	39.0x	₹1822 cr	7.0%	10.0%	0.6x
2024-10	37.3x	₹1822 cr	7.0%	10.0%	0.6x
2024-09	43.1x	₹1822 cr	7.0%	10.0%	0.6x
2024-08	33.8x	₹1817 cr	9.0%	10.0%	0.6x
2024-07	31.1x	₹1817 cr	9.0%	10.0%	0.6x
2024-06	30.4x	₹1817 cr	9.0%	10.0%	0.6x
2024-05	19.5x	₹1669 cr	14.3%	17.0%	0.3x
2024-04	21.2x	₹1669 cr	14.3%	17.0%	0.3x
2024-03	21.3x	₹1669 cr	14.3%	17.0%	0.3x
2024-02	22.6x	₹1669 cr	14.3%	17.0%	0.3x
2024-01	24.1x	₹1669 cr	14.3%	17.0%	0.3x
2023-12	25.6x	₹1669 cr	14.3%	17.0%	0.3x
2023-11	23.5x	₹1669 cr	14.3%	17.0%	0.3x
2023-10	20.6x	₹1669 cr	14.3%	17.0%	0.3x
2023-09	22.0x	₹1669 cr	14.3%	17.0%	0.3x
2023-08	20.5x	₹1669 cr	14.3%	17.0%	0.3x
2023-07	20.5x	₹1669 cr	14.3%	17.0%	0.3x
2023-06	21.2x	₹1669 cr	14.3%	17.0%	0.3x
2023-05	21.0x	₹1541 cr	17.7%	23.0%	0.3x
2023-04	19.3x	₹1541 cr	17.7%	23.0%	0.3x
2023-03	19.4x	₹1541 cr	17.7%	23.0%	0.3x
2023-02	21.4x	₹1541 cr	17.7%	23.0%	0.3x
2023-01	19.5x	₹1541 cr	17.7%	23.0%	0.3x
2022-12	24.2x	₹1541 cr	17.7%	23.0%	0.3x
2022-11	23.7x	₹1541 cr	17.7%	23.0%	0.3x
2022-10	21.1x	₹1541 cr	17.7%	23.0%	0.3x
2022-09	19.5x	₹1541 cr	17.7%	23.0%	0.3x
2022-08	21.3x	₹1541 cr	17.7%	23.0%	0.3x
2022-07	22.9x	₹1541 cr	17.7%	23.0%	0.3x
2022-06	21.8x	₹1541 cr	17.7%	23.0%	0.3x
2022-05	35.0x	₹1242 cr	12.5%	16.0%	0.3x
2022-04	37.7x	₹1242 cr	12.5%	16.0%	0.3x
2022-03	37.3x	₹1242 cr	12.5%	16.0%	0.3x
2022-02	38.8x	₹1242 cr	12.5%	16.0%	0.3x
2022-01	38.2x	₹1242 cr	12.5%	16.0%	0.3x
2021-12	45.0x	₹1242 cr	12.5%	16.0%	0.3x
2021-11	38.4x	₹1242 cr	12.5%	16.0%	0.3x
2021-10	46.1x	₹1242 cr	12.5%	16.0%	0.3x
2021-09	44.5x	₹1242 cr	12.5%	16.0%	0.3x
2021-08	47.5x	₹1242 cr	12.5%	16.0%	0.3x
2021-07	44.5x	₹1242 cr	12.5%	16.0%	0.3x
2021-06	40.9x	₹1242 cr	12.5%	16.0%	0.3x
2021-05	150.0x	₹1107 cr	3.6%	6.0%	0.4x
2021-04	125.4x	₹1107 cr	3.6%	6.0%	0.4x
2021-03	109.8x	₹1107 cr	3.6%	6.0%	0.4x
2021-02	111.0x	₹1107 cr	3.6%	6.0%	0.4x
2021-01	114.7x	₹1107 cr	3.6%	6.0%	0.4x
2020-12	116.0x	₹1107 cr	3.6%	6.0%	0.4x
2020-11	99.8x	₹1107 cr	3.6%	6.0%	0.4x
2020-10	98.0x	₹1107 cr	3.6%	6.0%	0.4x
2020-09	97.8x	₹1107 cr	3.6%	6.0%	0.4x
2020-08	87.4x	₹1107 cr	3.6%	6.0%	0.4x
2020-07	86.5x	₹1107 cr	3.6%	6.0%	0.4x
2020-06	77.8x	₹1107 cr	3.6%	6.0%	0.4x
2020-05	—	₹968 cr	-0.4%	1.0%	0.4x
2020-04	—	₹968 cr	-0.4%	1.0%	0.4x
2020-03	—	₹968 cr	-0.4%	1.0%	0.4x
2020-02	—	₹968 cr	-0.4%	1.0%	0.4x
2020-01	—	₹968 cr	-0.4%	1.0%	0.4x
2019-12	—	₹968 cr	-0.4%	1.0%	0.4x
2019-11	—	₹968 cr	-0.4%	1.0%	0.4x
2019-10	—	₹968 cr	-0.4%	1.0%	0.4x
2019-09	—	₹968 cr	-0.4%	1.0%	0.4x
2019-08	—	₹968 cr	-0.4%	1.0%	0.4x
2019-07	—	₹968 cr	-0.4%	1.0%	0.4x
2019-06	—	₹968 cr	-0.4%	1.0%	0.4x
2019-05	41.6x	₹1041 cr	6.3%	7.0%	0.4x
2019-04	44.7x	₹1041 cr	6.3%	7.0%	0.4x
2019-03	45.3x	₹1041 cr	6.3%	7.0%	0.4x
2019-02	39.3x	₹1041 cr	6.3%	7.0%	0.4x
2019-01	41.3x	₹1041 cr	6.3%	7.0%	0.4x

Methodology and data notes